Altimmune Inc (ALT) financials
Altimmune revenue and earnings by year
Altimmune's revenue was $41,000 in the fiscal year to December 31, 2025, up 105.0% from the year before. Net income was -$88.1 million, -214861.0% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 38.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 4 | 8 | 6 | 10 | 11 | 3 |
| Revenue growth | 105.0% | -95.3% | -90.3% | -46.1% | 41.1% | -43.8% | -3.8% | 231.8% | — |
| Operating income | -94 | -103 | -96 | -97 | -55 | -21 | -43 | -52 | -11 |
| Operating margin | -230461.0% | -515860.0% | -22518.5% | -2197.6% | -669.5% | -370.0% | -414.6% | -484.7% | -342.7% |
| Net income | -88 | -95 | -88 | -97 | -49 | -21 | -39 | -46 | -11 |
| Net margin | -214861.0% | -475295.0% | -20762.2% | -2201.6% | -599.2% | -353.7% | -379.2% | -432.3% | -342.6% |
| Diluted EPS | -$1.00 | -$1.34 | -$1.66 | -$2.35 | — | — | — | — | — |
| Free cash flow | -68 | -80 | -76 | -90 | -35 | -10 | -10 | -20 | -6 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ALT in Markets.
See also: ALT returns
No forecast, no recommendation. This page describes Altimmune Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.